Drug Details

General Information of the Drug (ID: DR7340)
Name
Brentuximab vedotin
Molecular Type
Antibody
Disease Hodgkin lymphoma [ICD-11: 2B30] Approved [1]
TTD Drug ID
D03TIS
DrugBank ID
DB08870
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Vinblastine      Catharanthus roseus     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 The results of the ECHELON-1 study showed a significantly longer modified progression-free survival (mPFS) following BV+AVD than with ABVD in primary HL.
Target and Pathway
Target(s) Lymphocyte activation antigen CD30 (TNFRSF8)  Molecule Info  [3]
KEGG Pathway Cytokine-cytokine receptor interaction Click to Show/Hide
NetPath Pathway Leptin Signaling Pathway Click to Show/Hide
2 TCR Signaling Pathway
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6772).
Reference 2 Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD). Intern Med. 2020 Sep 1;59(17):2165-2171.
Reference 3 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
 Download Picture         KEGG Link